Skip to main content
Terug
HTSUF logo

Hisamitsu Pharmaceutical Co., Inc.

Datakwaliteit: 100%
Overbought
HTSUF
OTC Healthcare Medical - Pharmaceuticals
€ 29,00
€ 0,00 (0,00%)
Marktkapitalisatie: 2,03B
Ook genoteerd als HTSUY OTC
Dagbereik
€ 29,00 € 29,00
52-Weeksbereik
€ 27,52 € 32,30
Volume
100
50D / 200D Gem.
€ 29,00 / € 28,99
Vorige Slotkoers
€ 29,00

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E 0,1 0,3
P/B 0,0 2,9
ROE % 8,0 3,7
Net Margin % 14,0 3,8
Rev Growth 5Y % 8,0 10,0
D/E 0,0 0,2

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 399,15
€ 383,68 – € 414,62
 190 B 1
FY2029 € 356,67
€ 342,84 – € 370,49
 180 B 1
FY2028 € 315,27
€ 303,05 – € 327,49
 170 B 1

Belangrijkste Punten

Revenue grew 8,04% annually over 5 years — modest growth
Earnings grew 55,76% over the past year
Debt/Equity of 0,01 — conservative balance sheet
Generating 4,99B in free cash flow
P/E of 0,09 — trading at a low valuation
PEG of 0,20 suggests growth is underpriced

Groei

Revenue Growth (5Y)
8,04%
Revenue (1Y)10,09%
Earnings (1Y)55,76%
FCF Growth (3Y)1,77%

Kwaliteit

Return on Equity
8,03%
ROIC5,05%
Net Margin13,95%
Op. Margin12,11%

Veiligheid

Debt / Equity
0,01
Current Ratio4,32
Interest Coverage821,52

Waardering

P/E Ratio
0,09
P/B Ratio0,01
EV/EBITDA-5,75
Dividend Yield0,02%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 10,09% Revenue Growth (3Y) 10,26%
Earnings Growth (1Y) 55,76% Earnings Growth (3Y) 36,13%
Revenue Growth (5Y) 8,04% Earnings Growth (5Y) 23,84%
Profitability
Revenue (TTM) 156,01B Net Income (TTM) 21,76B
ROE 8,03% ROA 6,34%
Gross Margin 58,46% Operating Margin 12,11%
Net Margin 13,95% Free Cash Flow (TTM) 4,99B
ROIC 5,05% FCF Growth (3Y) 1,77%
Safety
Debt / Equity 0,01 Current Ratio 4,32
Interest Coverage 821,52 Dividend Yield 0,02%
Valuation
P/E Ratio 0,09 P/B Ratio 0,01
P/S Ratio 0,01 PEG Ratio 0,20
EV/EBITDA -5,75 Dividend Yield 0,02%
Market Cap 2,03B Enterprise Value -108,63B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 156,01B 141,71B 128,33B 120,19B 114,51B
Net Income 21,76B 13,97B 11,74B 9,66B 9,25B
EPS (Diluted) 295,15 181,42 147,87 118,84 113,10
Gross Profit 91,20B 78,97B 72,70B 70,07B 69,17B
Operating Income 18,90B 13,17B 11,60B 9,34B 10,67B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 343,07B 328,78B 313,92B 302,86B 299,86B
Total Liabilities 63,67B 61,70B 55,51B 47,98B 46,06B
Shareholders' Equity 276,82B 264,87B 256,36B 253,17B 252,30B
Total Debt 3,86B 2,10B 2,30B 2,46B 1,60B
Cash & Equivalents 114,52B 112,46B 122,15B 129,29B 114,25B
Current Assets 203,79B 194,02B 199,17B 200,18B 198,06B
Current Liabilities 47,23B 45,94B 42,58B 32,16B 30,06B

Strategiescores

This stock passed the criteria for 3 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#537 of 827
35
Growth Price/Sales Ratio Focus (Ken Fisher)
#579 of 618
8
Value Defensive Investing (Benjamin Graham)
#667 of 709
3

Recente Activiteit

Ingestapt Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Ingestapt Defensive Investing (Benjamin Graham)
Mar 24, 2026